Abstract:647 Background: Combination chemotherapy with oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) showed improved survival compared to gemcitabine monotherapy for patients with metastatic pancreatic cancer and has become the one of the standard regimens. Despite of its clinical benefit, FOLFIRNIOX needs continuous infusion of 5-FU for 46 hours, which impairs patient’s quality of life. In other gastrointestinal cancer, infusion pump free regimens, in which oral 5-FU drug replace the continuous infusion of 5-FU, have developed as alternative regimen by its convenience. Therefore, we planned to develop new combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) for metastataic pancreatic cancer. Methods: HGCSG1803 study has conducted as a multicenter, non-randomized, single arm, phase II study in Japan. The chemotherapy-naïve patients with metastatic pancreatic cancer were eligible. S-1 (40 mg/m 2 ) orally intake twice daily for 14-day followed by a 14-day rest, and intravenous 65 mg/m 2 of L-OHP and 100 mg/m 2 of IRI on day 1 and day 15 every four weeks were continued until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by RECIST ver1.1, with a threshold of 10% and an expected value of 30%. The secondary endpoints were overall survival (OS), progression-free survival (PFS), and safety. Results: Between Jan 2020 and May 2022, forty patients were enrolled and 39 patients were included in full analysis set (one patient were excluded because of consent withdrawal). Median age was 66 (range, 41-75), female/male were 16/23, ECOG PS 0/1; 32/7, UGT1A1 wild /heterozygous for *6 or *28 allele 27/12, liver/lung/peritoneal metastasis 28/9/11, respectively. The median relative dose intensities of S-1, irinotecan, and oxaliplatin were 76%, 72%, and 70%, respectively. Objective response rate and disease control rate were 43.6% (95%CI 27.8-60.4%) and 76.9% (95%CI 60.4-89.1%), respectively. In the median follow-up time was 13.7 months, median progression free survival and overall survival were 4.3 months (95%CI 2.5-6.2 months) and 11.1 months (95%CI 7.2-14.9 months), respectively. Four patients discontinued protocol therapy due to adverse events (AE) without disease progression. Grade 3 or higher AE that occurred in more than 5% of patients were leucopenia (21%), hypokalemia (21%), neutropenia (18%), anemia (15%), hyponatremia (15%), ALT elevation (10%), anorexia (8%), nausea (5%), and febrile neutropenia (5%). One patient died due to protocol therapy (drug induced pneumonitis). Conclusions: OX-IRIS showed high response rate with manageable safety, and the primary endpoint was met. This new triplet regimen could be a useful first line treatment option for patients with metastatic pancreatic cancer. Clinical trial information: jRCTs011190008 .

[Clinical and laboratory investigation of patients with hematologic malignancies harboring der(1;7)(q10;p10)].

A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects

A Phase II Study of Biweekly Oxaliplatin Plus S-1 Combination Chemotherapy As a First-Line Treatment for Patients with Metastatic or Advanced Gastric Cancer in China

A decrease in serum 1,5‐anhydroglucitol levels is associated with the presence of a first‐degree family history of diabetes in a Chinese population with normal glucose tolerance

Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer

[Rate of renewal of noradrenalin in the vas deferens of the rat seminal vesicle].

Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer

A Randomized, Multicenter, Controlled Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined with Ts-1 (sox) Versus Sox or Oxaliplatin with Capecitabine (xelox) As Post-Operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma with D2 Dissection (resolve Trial)

Oxaliplatin Plus Irinotecan Vs Irinotecan As Second-Line Treatment in Pancreatic Cancer Patients: a Randomized-Controlled Open-Label Phase II Study

A Phase Iii Study of S-1 Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase Ii Study of Biweekly Oxaliplatin and S-1(Sox) As First-Line Combination Therapy in Patients with Advanced Gastric Cancer.

Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin

Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer A Randomized Clinical Trial

Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study

[Mechanism of transformation of human diploid cells by leukemogenic viruses. Study of the activity of the "excision-recombination" repair system].

Efficacy and Safety for Apatinib Combined with Oxaliplatin and S1 in Initially Treated Metastatic Gastric Cancer: A Single-Center Observational Study.

HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first line treatment.

[Phase II Clinical Trial of Oxaliplatin Alone for Refractory Advanced Colorectal Cancer].

S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.

Perioperative Versus Adjuvant S-1 Plus Oxaliplatin Chemotherapy for Stage II/III Resectable Gastric Cancer (RESONANCE): a Randomized, Open-Label, Phase 3 Trial

Phase I Dose-Escalating Study of S-1 in Combination with Oxaliplatin for Patients with Advanced And/or Metastatic Colorectal Cancer